Literature DB >> 20348556

Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases.

M H van den Berg1, E van Dulmen-den Broeder, A Overbeek, J W R Twisk, R Schats, F E van Leeuwen, G J Kaspers, C B Lambalk.   

Abstract

OBJECTIVE: The aim of this study was to evaluate whether values of FSH, LH, estradiol, anti-Müllerian hormone (AMH), inhibin B, antral follicle count (AFC) and ovarian volume (OV) determined on day 7 of the hormone-free interval are similar to values measured on days 2-5 of two subsequent natural menstrual cycles. In addition, values measured on day 7 of the hormone-free interval were examined for the purpose of predicting values measured on days 2-5 during the second natural cycle.
METHODS: In this study, 25 women using hormonal contraception provided a blood sample and underwent transvaginal ultrasound measurements on day 7 of the hormone-free interval and on cycle days 2-5 of two subsequent natural cycles. Changes were compared by repeated measures ANOVA and multivariate linear regression was used for prediction purposes.
RESULTS: Mean (SD) age of the participants was 26.3 (6.2) years. Overall significant decreases in FSH and inhibin B and significant increases in AMH, AFC and ovarian volume values were measured after discontinuation of hormonal contraception (P < 0.001, P = 0.04, P = 0.01, P < 0.001 and P = 0.004, respectively). Significant changes occurred both from day 7 of the hormone-free interval to natural cycle 1 as well as from natural cycle 1 to natural cycle 2. FSH, AMH and AFC values measured during days 2-5 of natural cycle 2 could be predicted by the corresponding values measured on day 7 of the hormone-free interval.
CONCLUSION: Hormonal and ultrasound markers of ovarian function in hormonal contraception users measured at the end of the hormone-free interval do not seem to represent subsequent natural early follicular phase values. However, these values can, in some cases (FSH, AMH and AFC), be used to predict early follicular phase values using calculated prediction equations, which need to be validated in future research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348556     DOI: 10.1093/humrep/deq071

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  22 in total

1.  Impact of cancer therapies on ovarian reserve.

Authors:  Clarisa R Gracia; Mary D Sammel; Ellen Freeman; Maureen Prewitt; Claire Carlson; Anushree Ray; Ashley Vance; Jill P Ginsberg
Journal:  Fertil Steril       Date:  2011-12-02       Impact factor: 7.329

2.  Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield.

Authors:  Joseph M Letourneau; Hakan Cakmak; Molly Quinn; Nikita Sinha; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-07-01       Impact factor: 3.412

3.  BRCA1 germline mutations may be associated with reduced ovarian reserve.

Authors:  Erica T Wang; Margareta D Pisarska; Catherine Bresee; Yii-Der Ida Chen; Jenny Lester; Yalda Afshar; Carolyn Alexander; Beth Y Karlan
Journal:  Fertil Steril       Date:  2014-09-23       Impact factor: 7.329

4.  Serum antimüllerian hormone in healthy premenopausal women.

Authors:  Christiana M Shaw; Frank Z Stanczyk; Brian L Egleston; L L Kahle; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2011-06-30       Impact factor: 7.329

5.  Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers.

Authors:  M A Spath; T B Feuth; E G Allen; A P T Smits; H G Yntema; A Geurts van Kessel; D D M Braat; S L Sherman; C M G Thomas
Journal:  Hum Reprod       Date:  2011-05-15       Impact factor: 6.918

6.  Anti-Müllerian hormone screening to assess ovarian reserve among female survivors of childhood cancer.

Authors:  Anne-Marie Charpentier; Amy Lee Chong; Genevieve Gingras-Hill; Sameera Ahmed; Candemir Cigsar; Abha A Gupta; Ellen Greenblatt; David C Hodgson
Journal:  J Cancer Surviv       Date:  2014-05-09       Impact factor: 4.442

7.  Novel correlates between antimüllerian hormone and menstrual cycle characteristics in African-American women (23-35 years-old).

Authors:  Erica E Marsh; Lia A Bernardi; Marissa L Steinberg; Peter J de Chavez; Jenny A Visser; Mercedes R Carnethon; Donna D Baird
Journal:  Fertil Steril       Date:  2016-04-23       Impact factor: 7.329

8.  Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens.

Authors:  Alison Leiper; Maite Houwing; E Graham Davies; Kanchan Rao; Siobhan Burns; Emma Morris; Joop Laven; Anne-Lotte van der Kooi; Marry van den Heuvel Eibrink; Stephen Nussey
Journal:  Bone Marrow Transplant       Date:  2020-03-30       Impact factor: 5.483

9.  Association of oral contraceptives and tubal ligation with antimüllerian hormone.

Authors:  Christine R Langton; Brian W Whitcomb; Alexandra C Purdue-Smithe; Lynnette L Sievert; Susan E Hankinson; JoAnn E Manson; Bernard A Rosner; Elizabeth R Bertone-Johnson
Journal:  Menopause       Date:  2021-12-06       Impact factor: 2.953

10.  Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? A pilot study.

Authors:  David H Barad; Ann Kim; Hala Kubba; Andrea Weghofer; Norbert Gleicher
Journal:  Reprod Biol Endocrinol       Date:  2013-04-04       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.